Current Report Filing (8-k)
December 30 2022 - 3:16PM
Edgar (US Regulatory)
0001624326
false
0001624326
2022-12-29
2022-12-29
0001624326
PAVM:CommonStockParValue0.001PerShareMember
2022-12-29
2022-12-29
0001624326
PAVM:SeriesZWarrantsToPurchaseCommonStockMember
2022-12-29
2022-12-29
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): December 29, 2022
PAVMED
INC. |
(Exact
Name of Registrant as Specified in Charter) |
Delaware |
|
001-37685 |
|
47-1214177 |
(State
or Other Jurisdiction
of
Incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
One
Grand Central Place, Suite 4600, New York, New York |
|
10165 |
(Address
of Principal Executive Offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (212) 949-4319
N/A |
(Former
Name or Former Address, if Changed Since Last Report) |
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425). |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12). |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)). |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)). |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, Par Value $0.001 Per Share |
|
PAVM |
|
The
Nasdaq Stock Market LLC |
Series
Z Warrants to Purchase Common Stock |
|
PAVMZ |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
3.01. | Notice
of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
On
December 29, 2022, PAVmed Inc. (the “Company”) received a notice from the Listing Qualifications Department of The
Nasdaq Stock Market LLC (“Nasdaq”) stating that, for the prior 30 consecutive business days (through December 28,
2022), the closing bid price of the Company’s common stock had been below the minimum of $1 per share required for continued listing
on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2).
The
notification letter stated that the Company would be afforded 180 calendar days (until June 27, 2023) to regain compliance. In order
to regain compliance, the closing bid price of the Company’s common stock must be at least $1 for a minimum of ten consecutive
business days. The notification letter also stated that, in the event the Company does not regain compliance within the initial 180-day
period, the Company may be eligible for an additional 180-day period. If the Company is not eligible for the additional 180-day period,
or if it appears to the Nasdaq staff that the Company will not be able to cure the deficiency, the Nasdaq Listing Qualifications Department
will provide notice after the end of the initial 180-day period that the Company’s securities will be subject to delisting.
The
Nasdaq notification has no effect at this time on the listing of the Company’s common stock or Series Z warrants, and the common
stock and Series Z warrants will continue to trade uninterrupted under the symbol “PAVM” and “PAVMZ,” respectively.
The Company intends to consider all available options to regain compliance with the Nasdaq listing standards.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Dated:
December 30, 2022
|
PAVMED
INC. |
|
|
|
By: |
/s/
Dennis M. McGrath |
|
|
Dennis
M. McGrath |
|
|
President
and Chief Financial Officer |
PAVmed (NASDAQ:PAVMW)
Historical Stock Chart
From May 2024 to Jun 2024
PAVmed (NASDAQ:PAVMW)
Historical Stock Chart
From Jun 2023 to Jun 2024
Real-Time news about PAVmed Inc (NASDAQ): 0 recent articles
More Pavmed Inc. News Articles